List of Publications                                                                    G.J.L.H. van LeendersList of Publi...
List of Publications                                                                  G.J.L.H. van Leenders67) T. Wolters,...
List of Publications                                                                   G.J.L.H. van Leenders54) T. Wolters...
List of Publications                                                                   G.J.L.H. van Leenders39) R.A. Alwan...
List of Publications                                                                G.J.L.H. van Leenders24) M.N. van der ...
List of Publications                                                                   G.J.L.H. van Leenders8) G.J.L.H. va...
Upcoming SlideShare
Loading in …5

List of Publications


Published on

List of publications

  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

List of Publications

  1. 1. List of Publications G.J.L.H. van LeendersList of Publications (update March 1rst, 2012)77) C. Schroten, N.F. Dits, E.W. Steyerberg, R. Kranse, G. van Leenders, C.H. Bangma, R. Kraaij: Theadditional value of TGFβ1 and IL-7 to predict the course of prostate cancer progression. Cancer ImmunolImmunother 2011; Epub ahead of print. IF 4.376) G.J.L.H. van Leenders, R. Sookhlall, W.J. Teubel, C.M.A. de Ridder, S. Reneman, A. Sacchetti, C.J.Vissers, W. van Weerden, G. Jenster: Activation of c-MET induces a stem-like phenotype in human prostatecancer. PLOS One 2011; 6: e26753. IF 4.475) M.J. Roobol, H.A. van Vugt, S. Loeb, X. Zhu, M. Bul, C.H. Bangma, G. van Leenders, E.W. Steyerberg,F.H. Schröder: Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination inthe ERSPC risk calculators. Eur Urol 2012; 61: 577-583. IF 8.874) A.M. Hoogland, G. Jenster, W.M. van Weerden, J. Trapman, T. van der Kwast, M.J. Roobol, F.H.Schröder, M.F. Wildhagen, G.J.L.H. van Leenders: ERG immunohistochemistry is not predictive for PSArecurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer. Mod Pathol2011; Epub ahead of print. IF 4.273) B.W. van Rhijn, T.H. van der Kwast, S.S. Alkhateeb, N.E. Fleshner, G.J. van Leenders, P.J. Bostrom,M.N. van der Aa, D.M. Kakiashvili, C.H. Bangma, M.A. Jewett, A.R. Zlotta: A new and highly prognosticsystem to discern T1 bladder cancer substage. Eur Urol 2012; 61: 378-384. IF 8.872) M.A. Rijlaarsdam, H.A. van Herk, A.J. Gillis, H. Stoop, G. Jenster, J. Martens, G.J. van Leenders, W.Dinjens, A.M. Hoogland, M. Timmermans, L.H. Looijenga: Specific detection of OCT3/4 isoform A/B/B1expression in solid (germ cell) tumours and cell lines: confirmation of OCT3/4 specificity for germ celltumours. Br J Cancer 2011; Epub ahead of print. IF 4.871) E.S. Martens-Uzunova, S.E. Jalava, N.F. Dits, G.J. van Leenders, S. Møller, J. Trapman, C.H. Bangma,T. Litman, T. Visakorpi, G. Jenster: Diagnostic and prognostic signatures from the small non-coding RNAtranscriptome in prostate cancer. Oncogene 2012; 31: 978-991. IF 7.470) G. van Soest, E. Regar, T.P. Goderie, N. Gonzalo, S. Koljenović, G.J. van Leenders, P.W. Serruys, A.F.van der Steen: Pitfalls in Plaque Characterization by OCT Image Artifacts in Native Coronary Arteries. JACCCardiovasc Imaging 2011; 4: 810-813. IF 5.569) B. Furusato, G.J. van Leenders, J. Trapman, T. Kimura, S. Egawa, H. Takahashi, M. Furusato, T.Visakorpi, H. Hano: Immunohistochemical ETS-related gene detection in a Japanese prostate cancer cohort:diagnostic use in Japanese prostate cancer patients. Pathol Int 2011; 61: 409-414. IF 1.568) A Broeks, M.K. Schmidt, M.E. Sherman, F.J. Couch, J.L. Hopper, G.S. Dite, C. Apicella, L.D. Smith, F.Hammet, M.C. Southey, L.J. van t Veer, R. de Groot, V.T. Smit, P.A. Fasching, M.W. Beckmann, S. Jud,A.B. Ekici, A. Hartmann, A. Hein, R. Schulz-Wendtland, B. Burwinkel, F. Marme, A. Schneeweiss, H.P. Sinn,C. Sohn, S. Tchatchou, S.E. Bojesen, B.G. Nordestgaard, H. Flyger, D.D. Orsted, D. Kaur-Knudsen, R.L.Milne, J.I. Pérez, P. Zamora, P.M. Rodríguez, J. Benítez, H. Brauch, C. Justenhoven, Y.D. Ko, U. Hamann,H.P. Fischer, T. Brüning, B. Pesch, J. Chang-Claude, S. Wang-Gohrke, M. Bremer, J.H. Karstens, P.Hillemanns, T. Dörk, H.A. Nevanlinna, T. Heikkinen, P. Heikkilä, C. Blomqvist, K. Aittomäk, K. Aaltonen, A.Lindblom, S. Margolin, A. Mannerma, V.M. Kosma, J.M. Kauppinen, V. Kataja, P. Auvinen, M. Eskelinen, Y.Soini, G. Chenevix-Trench, A.B. Spurdle, J. Beesley, X. Chen, H. Holland, D. Lambrechts, B. Claes, T.Vandorpe, P. Neven, H. Wildiers, D. Flesch-Janys, R. Hein, T. Löning, M. Kosel, Z.S. Fredericksen, X.Wang, G.G. Giles, L. Baglietto, G. Severi, C. McLean, C.A. Haiman, B.E. Henderson, L. Le Marchand, L.N.Kolonel, G.G. Alnæs, V. Kristensen, A.L. Børresen-Dale, D.J. Hunter, S.E. Hankinson, I.L. Andrulis, A.M.Mulligan, F.P. OMalley, P. Devilee, P. Huijts, R.A. Tollenaar, C.J. van Asperen, C. Seynaeve, S.J. Chanock,J. Lissowska, L. Brinton, B. Peplonska, J. Figueroa, X.R. Yang, M.J. Hooning, A. Hollestelle, R.A. Oldenburg,A. Jager, M. Kriege, B. Ozturk, G.J. van Leenders, P. Hall, K. Czene, K. Humphreys, J. Liu, A. Cox, D.Connley, H.E. Cramp S.S. Cross, S.P. Balasubramanian, M.W. Reed, A.M. Dunning, D.F. Easton, M.K.Humphreys, C. Caldas, J. Lubinski, A. Jakubowska, T. Huzarski, T. Byrski, C. Cybulski, B. Gorski, J.Gronwald, P. Brennan, S. Sangrajrang, V. Gaborieau, C.Y. Shen, C.N. Hsiung, J.C. Yu, S.T. Chen, G.C.Hsu, M.F. Hou, C.S. Huang, H. Anton-Culver, A. Ziogas, P.D. Pharoah, M. Garcia-Closas. Low penetrancebreast cancer susceptibility foci are associated with specific breast tumor subtypes: findings from the BreastCancer Association Consortium. Hum Mol Genet 2011; 20: 3289-3303. IF 8.1 1
  2. 2. List of Publications G.J.L.H. van Leenders67) T. Wolters, R. Montironi, R. Mazzucchelli, M. Scarpelli, M.J. Roobol, R.C. van den Bergh, P.J. vanLeeuwen, R.F. Hoedemaeker, G.J. van Leenders, F.H. Schröder, T.H. van der Kwast: Comparison ofincidentally detected prostate cancer with screen-detected prostate cancer treated by prostatectomy.Prostate 2012; 72: 108-115. IF 3.466) G.J.L.H. van Leenders, J.L. Boormans, C.J. Vissers, A.M. Hoogland, A.A.J.W.M. Bressers, B. Furusato,J. Trapman. Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications forpathology practice. Mod Pathol 2011; 24: 1128-1138. IF 4.265) A.M. Hoogland, A. Dahlman, K.J. Vissers, T. Wolters, F.H. Schröder, M.J. Roobol, A.S. Bjartell, G.J.L.H.van Leenders: CRISP-3 and β-MSP on prostate cancer needle-biopsies do not have predictive value forsubsequent prostatectomy outcome. BJU Int 2011; Epub ahead of print. IF 3.264) T. Wolters, M.J. Roobol, P.J. van Leeuwen, R.C.N. van den Bergh, R.F. Hoedemaeker, G.J.L.H. vanLeenders, F.H. Schröder, T.H. van der Kwast: A critical analysis of the tumor volume threshold for clinicallyinsignificant prostate cancer using a data set of a randomized screening trial. J Urol 2011; 185: 121-125. IF3.963) T.C. Zuiverloon, J.L. Boormans, J. Trapman, G.J.L.H. van Leenders, E.C. Zwarthoff: No evidence ofFGFR3 mutations in prostate cancer. Prostate 2010; 71: 637-641. IF 3.462) M.J. Roobol, F.H. Schroder, G.J. van Leenders, D. Hessels, R.C. van den Bergh, T. Wolters, P.J. vanLeeuwen: Performance of Prostate Cancer Antigen 3 (PCA3) and prostate-specific antigen in prescreenedmen: reproducibility and detection characteristics for prostate cancer patients with PCA3 scores (≥100). EurUrol 2010; 58: 893-899. IF 8.861) B.W.G. van Rhijn, T.C. Zuiverloon, A.N. Vis, F. Radvanyi, G.J.L.H. van Leenders, B.C.M. Ooms, W.J.Kirkels, G.A. Lockwood, E.R. Boevé, A.C. Jöbsis, E.C. Zwarthoff, T.H. van der Kwast: Molecular grade(FGFR3/MIB-1) and EORTC risk-scores are predictive in primary non-muscle-invasive bladder cancer. EurUrol 2010; 58: 433-441. IF 8.860) M.J. Roobol, F.H. Schroder, P. van Leeuwen, T. Wolters, R.C. van den Bergh, G.J.L.H. van Leenders,D. Hessels: Performance of the Prostate Cancer Antigen 3 (PCA3) gene and prostate-specific antigen inprescreened men: exploring the value of PCA3 for a first-line diagnostic test. Eur Urol 2010; 58: 475-481. IF8.859) L. Bañez, L. Sun, G.J.L.H. van Leenders, T.M. Wheeler, C.H. Bangma, S.J. Freedland, M.M. Ittmann,A.L. Lark, J.F. Madden, A. Hartman, G. Weiss, E. Castaños-Vélez: Clinical validation of PITX2 methylationas a predictor of high risk PSA recurrence in post-radical prostatectomy prostate cancer patients. J Urol2010; 184: 149-156. IF 3.958) J.L. Boormans, H. Korsten, A.C. Ziel-van der Made, G.J.L.H. van Leenders, P.C. Verhagen, J.Trapman: E17K substitution in AKT1 in prostate cancer. Br J Cancer 2010; 102: 1491-1494. IF 4.857) T.P. Goderie, G. van Soest, H.M. Garcia-Garcia, N. Gonzalo, S. Koljenović, G.J.L.H. van Leenders, F.Mastik, E. Regar, J.W. Oosterhuis, P.W. Serruys, A.F. van der Steen: Combined optical coherencetomography and intravascular ultrasound radio frequency data analysis for plaque characterization.Classification accuracy of human coronary plaques in vitro. Int J Cardiovasc Imaging 2010; 26: 843-850. IF2.556) G. van Soest, T. Goderie, E. Regar, S. Koljenović, G.J.L.H. van Leenders, N. Gonzalo, S. van Noorden,T. Okamura, B.E. Bouma, G.J. Tearney, J.W. Oosterhuis, P.W. Serruys, A.F. van der Steen: Atherosclerotictissue characterization in vivo by optical coherence tomography attenuation imaging. J Biomed Opt 2010; 15:15: 011105 Epub ahead of print. IF 3.255) Th.H. van der Kwast, A. Evans, G. Lockwood, D. Tkachuk, K. Watson, D.G. Bostwick, J.I. Epstein, P.A.Humphrey, R. Montironi, G.J.L.H. van Leenders, C-G. Pihl, I. Neetens, P. Martikainen, M. Laurila, C.Mazerolles, L. Bubendorf, J. Srigley: Variability of diagnostic opinion among pathologists for single smallatypical foci in prostate biopsies. Am J Surg Path 2010; 34: 169-177. IF 5.2 2
  3. 3. List of Publications G.J.L.H. van Leenders54) T. Wolters, M.J. Roobol, P.J. van Leeuwen, R.C. van den Bergh, R.F. Hoedemaeker, G.J.L.H. vanLeenders, F.H. Schröder, T.H. van der Kwast: Should Pathologists Routinely Report Prostate TumourVolume? The Prognostic Value of Tumour Volume in Prostate Cancer. Eur Urol 2010; 57: 821-829. IF 8.853) J.L. Boormans, K.G. Hermans, A.C. Made, G.J.L.H. van Leenders, M.F. Wildhagen, L. Collette, F.H.Schröder, J. Trapman, P.C. Verhagen: Expression of the Androgen-Regulated Fusion Gene TMPRSS2-ERGDoes Not Predict Response to Endocrine Treatment in Hormone-Naïve, Node-Positive Prostate Cancer. EurUrol 2010; 57: 830-835. IF 8.852) B.W.G. van Rhijn, G.J.L.H. van Leenders, B.C.M. Ooms, W.J. Kirkels, A.L. Zlotta, E.R. Boevé, A.C.Jöbsis, T.H. van der Kwast: The pathologist’s mean grade is constant and individualizes the prognostic valueof bladder cancer grading. Eur Urol 2010; 57: 1052-1057. IF 8.851) T. Wolters, C.J. Vissers, C.H. Bangma, F.H. Schröder, G.J.L.H. van Leenders: The value of EZH2,p27(kip1), BMI-1 and MIB-1 on biopsy specimens with low risk prostate cancer in selecting men withsignificant prostate cancer at prostatectomy. BJU Int 2010; 106: 280-286. IF 3.250) J. Hofland, W.M. van Weerden, N.F.J. Dits, J. Steenbergen, G.J.L.H. van Leenders, G. Jenster, F.H.Schröder, F.H. de Jong: Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer.Cancer Res 2010; 70: 1256-1264. IF 8.249) T. Wolters, Th.H. van der Kwast , C.J. Vissers, M. Roobol, F.H. Schröder, G.J.L.H. van Leenders:False-negative prostate needle-biopsies during histological examination: identification, characterization andclinical follow-up. Am J Surg Path 2010; 34: 35-43. IF 5.248) G. van Soest, T.P. Goderie, N. Gonzalo, S. Koljenović, G.J.L.H. van Leenders, E. Regar, P.W. Serruys,A.F. van der Steen: Imaging atherosclerotic plaque composition with intracoronary optical coherencetomography. Neth Heart J 2009; 17: 448-450. IF 1.447) K.G. Hermans, J.L. Boormans, D. Gasi, G.J.L.H. van Leenders, G. Jenster, P. Verhagen, J. Trapman:Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorableprognosis of prostate cancer. Clin Cancer Res 2009; 15: 6398-6403. IF 7.346) R.R. Jurhill, J.H. van der Veen, G.J.L.H. van Leenders, P.C.M.S. Verhagen: Reduction of serum-PSAlevels following varicella zoster infection and valaciclovir treatment in local prostate cancer. Eur Urol 2009;56: 392-394. IF 8.845) M.A. den Bakker, B. Beverloo, M. van Noesel, C. Meeuwis, G.J.L.H. van Leenders: Extra-axial NUTtranslocation carcinoma ex-pleomorphic adenoma of the parotis gland. Am J Surg Path 2009; 33: 1253-1258. IF 5.244) L. Egevad, F. Algaba, D.M. Berney, L. Boccon-Gibod, D.F. Griffiths, A. Lopez-Beltran, G. Mikuz, M.Varma, R. Montironi, European Network of Uropathology: The European Network of Uropathology: anovel mechanism for communication between pathologists Anal Quant Cytol Histol 2009; 31: 90-95. IF 0.643) F.H. Schröder, J. Hugosson, M.J. Roobol, T.L. Tammela, S. Ciatto, V. Nelen, M. Kwiatkowski, M. Lujan,H. Lilja, M. Zappa, L.J. Denis, F. Recker, A. Berenguer, L. Määttänen, C.H. Bangma, G. Aus, A. Villers, X.Rebillard, T. van der Kwast, B.G. Blijenberg, S.M. Moss, H.J. de Koning, A. Auvinen, ERSPC Investigators:Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-1328. IF 53.542) L.M.G. Moons, F.H. Wolfhagen, R. Beukers, R.A. de Man, G.J.L.H. van Leenders, H.R. van Buuren: arare cause of large liver cysts. Am J Gastroenterology 2009; 104: 1056-1058. IF 6.941) J.G. van Roermund, D.E. Kok, M.F. Wildhagen, L.A. Kiemeney, F. Struik, S. Sloot, I.M. van Oort, C.A.Hulsbergen-van de Kaa, G.J.L.H. van Leenders, C.H. Bangma, J.A. Witjes: Body mass index as aprognostic marker for biochemical recurrence in Dutch men treated with radical prostatectomy. BJU Int 2009;104: 321-324. IF 3.240) R.C. van den Bergh, T. Wolters, M.C. Spaander, F.H. Schröder, G.J.L.H. van Leenders: Non-prostaticpathology on needle-biopsy - colorectal carcinoid: a case report: Cases J 2009; 2: 75. IF 0.6 3
  4. 4. List of Publications G.J.L.H. van Leenders39) R.A. Alwani, S.J.C.M.M. Neggers, M. van der Klift, M.G.A. Baggen, G.J.L.H. van Leenders, M.O. vanAken, W.W. de Herder, A.J. van der Lely, R.A. Feelders: Cushing’s syndrome due to ectopic ACTHproduction by (neuroendocrine) prostate carcinoma. Pituitary 2009; 12: 280-283. IF 2.338) J.L. Boormans, K.G. Hermans, G.J.L.H. van Leenders, J. Trapman, P.C.M.S. Verhagen: An activatingmutation in AKT1 in human prostate cancer. Int J Cancer 2008; 123: 2725-2726. IF 4.937) A. Al-Mamgani, W.L.J. van Putten, W.D. Heemsbergen, G.J.L.H. van Leenders, A. Slot, M.F.H.Dielwart, L. Incrocci, J.V. Lebesque: Update of the Dutch multicenter dose escalation trial of radiotherapy forlocalized prostate cancer. Int J Rad Oncol Biol Phys 2008; 72: 980-988. IF 4.536) C-L Lai, R. van den Ham, G.J.L.H. van Leenders, J. van der Lugt, E. Teske: Histopathological andimmunohistochemical characterization of canine prostate cancer. Prostate 2008; 68: 477-488. IF 3.435) C-L Lai, R. van den Ham, G.J.L.H. van Leenders, J. van der Lugt, E. Teske: Comparativecharacterization of the canine normal prostate in intact and castrated animals. Prostate 2008; 68: 498-507.IF 3.434) J.L. Boormans, M.F. Wildhagen, C.H. Bangma, P.C.M.S. Verhagen, G.J.L.H. van Leenders: Histologicalcharacterization of lymph node metastases in prostate cancer: correlation with cancer specific survival. BJUInt 2008; 102: 1589-1593. IF 3.233) C. Gosselaar, M.J. Roobol, S. Roemeling, T. Wolters, G.J.L.H. van Leenders, F.H. Schröder: The valueof an additional hypoechoic lesion-directed biopsy core for the detection of prostate cancer. BJU Int 2008;101: 685-690. IF 3.232) T. Wolters, M.J. Roobol, F.H. Schröder, T.H. van der Kwast, S. Roemeling, I.W. van der Cruijsen-Koeter,C.H. Bangma, G.J.L.H. van Leenders: Can non-malignant biopsy features identify men at increased risk ofbiopsy-detectable prostate cancer at re-screening after four years? (ERSPC Rotterdam section). BJU Int2008; 101: 283-288. IF 3.231) M.T. Kummeling, B.W. de Jong, C. Laffeber, D.J. Kok, P.C. Verhagen, G.J.L.H. van Leenders, R.H. vanSchaik, C.S. van Woerden, A. Verhulst, C.F. Verkoelen: Tubular and interstitial nephrocalcinosis. J Urol2007; 178: 1097-1103. IF 3.930) R. Postma, F.H. Schröder, G.J.L.H. van Leenders, R.F. Hoedemaeker, A.N. Vis, M.J. Roobol, T.H. vander Kwast: Cancer detection and cancer characteristics in the European Randomized Study of Screening forProstate Cancer (ERSPC) – section Rotterdam: a comparison of two rounds of screening. Eur Urol 2007; 52:89-97. IF 8.829) S. Roemeling, M.J. Roobol, S.H. de Vries, T. Wolters, C. Gosselaar, G.J.L.H. van Leenders, F.H.Schröder: Active surveillance for prostate cancer detected in three subsequent rounds of a screening trial:characteristics, PSA doubling times, and outcome. Eur Urol 2007; 51: 1244-1250. IF 8.828) G.J.L.H. van Leenders, D. Dukers, D. Hessels, S.W. van den Kieboom, C.A. Hulsbergen, J.A. Witjes,A.P. Otte, C.J. Meijer, F.M. Raaphorst: Polycomb-group oncogenes EZH2, BMI1, and RING1 areoverexpressed in prostate cancer with adverse pathologic and clinical features. Eur Urol 2007; 52: 455-463.IF 8.827) A.M. DeMarzo, E.A. Platz, J.I. Epstein, T. Ali, A. Billis, T.Y. Chan, L. Cheng, M. Datta, L. Egevad, D.Ertoy-Baydar, X. Farre, S.W. Fine, K.A. Iczkowski, M. Ittmann, B.S. Knudsen, M. Loda, A. Lopez-Beltran, C.Magi-Galluzzi, G. Mikuz, R. Montironi, E. Pikarsky, G. Pizov, M.A. Rubin, H. Samaratunga, T. Sebo, I.A.Sesterhenn, R.B. Shah, S. Signoretti, J. Simko, G. Thomas, P. Troncoso, T.T. Tsuzuki, G.J.L.H. vanLeenders, X.J. Yang, M. Zhou, W.D. Figg, A. Hoque, M.S. Lucia: A working group classification of focalprostate atrophy lesions. Am J Surg Pathol 30; 2006: 1281-1291. IF 5.226) R. Postma, G.J.L.H. van Leenders, M.J. Roobol, F.H. Schröder, T.H. van der Kwast: Tumour features inthe control and screening arm of a randomized trial of prostate cancer. Eur Urol 50; 2006: 70-75. IF 8.825) S. Roemeling, G.J.L.H. van Leenders, F.H. Schröder: Very late local recurrence after surgery forprostate cancer unaccompanied by detectable PSA levels. Prostate Cancer Prostatic Dis 2006; 6: 192-194.IF 2.3 4
  5. 5. List of Publications G.J.L.H. van Leenders24) M.N. van der Aa, G.J.L.H. van Leenders, E.W. Steyerberg, B.W. van Rhijn, A.C. Jobsis, E.C. Zwarthoff,T.H. van der Kwast: A new system for substaging pT1 papillary bladder cancer: a prognostic evaluation.Hum Pathol 2005; 36: 981-986. IF 3.023) T.H. van der Kwast, R. Postma, R.F. Hoedemaeker, G.J.L.H. van Leenders, F.H. Schröder: Features ofprostate cancers detected during a prevalence screening round. The Rotterdam experience. Can J Urol2005; 12 (Suppl 3): 16-20. IF 0.822) F.A. van Dorsten, M. van der Graaf, M.R.W. Engelbrecht, G.J.L.H. van Leenders, A. Verhofstad, M.Rijpkema, J.J.M.C.H. de la Rosette, J.O. Barentsz, A. Heerschap: Combined quantitative dynamic contrast-enhanced MR imaging and 1H MR spectroscopic imaging of human prostate cancer. J Magn Reson Imaging2004; 20: 279-287. IF 2.721) J.A. Schalken, G.J.L.H. van Leenders: Cellular and molecular biology of the prostate epithelial stemcell. Urology 2003; 62 (Suppl 1): 11-20. IF 2.320) M.R. Engelbrecht, H.J. Huisman, R.J. Laheij, G.J. Jager, G.J.L.H. van Leenders, C.A. Hulsbergen-vande Kaa, J.J. de la Rosette, J.G. Blickman, J.O. Barentsz: Discrimination of prostate cancer from normalperipheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. Radiology 2003;29: 248-254. IF 6.119) G.J.L.H. van Leenders, J.A. Schalken: Epithelial cell differentiation in the human prostate epithelium:implications for the pathogenesis and therapy of prostate cancer. Crit Rev Oncol Hematol 2003; 46 (Suppl):3-10. IF 4.718) D. Hessels, J.M. Klein Gunnewiek, I. van Oort, H.F. Karthaus, G.J.L.H. van Leenders, B. van Balken,L.A. Kiemeney, J.A. Witjes, J.A. Schalken: DD3(PCA3)-based molecular urine analysis for the diagnosis ofprostate cancer. Eur Urol 2003; 44: 8-15. IF 8.817) G.J.L.H. van Leenders, W.R. Gage, J.L. Hicks, B. van Balken, T.W. Aalders, J.A. Schalken, A.M. DeMarzo: Intermediate cells in human prostate epithelium are enriched in proliferative inflammatory atrophy.Am J Pathol 2003; 162: 1529-1537. IF 5.216) T.E. Goosens, J.J. de la Rosette, C.A. Hulsbergen-van de Kaa, G.J.L.H. van Leenders, H. Wijkstra: Thevalue of dynamic contrast enhanced power Doppler ultrasound imaging in the localization of prostate cancer.Eur Urol 2003; 43: 124-131. IF 8.815) J.P. Sedelaar, G.J.L.H. van Leenders, T.E. Goosens, C.A. Hulsbergen-van de Kaa, N.P. van Adrichem,H. Wijkstra, J.J. de la Rosette: Value of contrast ultrasonography in the detection of significant prostatecancer: correlation with radical prostatectomy specimens. Prostate 2002; 52: 246-253. IF 3.414) G.J.L.H. van Leenders, B. van Balken, T.A. Aalders, C.A. Hulsbergen-van de Kaa, D.J. Ruiter, J.A.Schalken: Intermediate cells in normal and malignant prostate epithelium express c-MET: implications forprostate cancer invasion. Prostate 2002; 51: 98-107. IF 3.413) J.P. Sedelaar, J.G. van Roermund, G.J.L.H. van Leenders, C.A. Hulsbergen-van de Kaa, H. Wijkstra,J.J.M.C.H. de la Rosette: Three-dimensional grayscale ultrasound: evaluation of prostate cancer comparedwith benign prostatic hyperplasia. Urology 2001; 57: 914-920. IF 2.312) G.J.L.H. van Leenders, J.A. Schalken: Stem cell differentiation within the human prostate epithelium:implications for prostate carcinogenesis. BJU Int 2001; 88 (Suppl 2): 35-42. IF 3.211) G.J.L.H. van Leenders, T.W. Aalders, C.A. Hulsbergen-van de Kaa, D.J. Ruiter, J.A. Schalken:Expression of basal cell keratins in human prostate cancer metastases and cell lines. J Pathol 2001; 195:563-570. IF 7.310) J.P. Sedelaar, G.J.L.H. van Leenders, C.A. Hulsbergen-van de Kaa, H.G. van der Poel, J.A. van derLaak, F.M.J. Debruyne, H. Wijkstra, J.J.M.C.H. de la Rosette: Microvessel density: correlation betweencontrast ultrasonography and histology of prostate cancer. Eur Urol 2001; 40: 285-293. IF 8.89) K. Tomita, A. van Bokhoven, G.J.L.H. van Leenders, T.E.G. Ruijter, C.F.J. Jansen, M.J.G. Bussemakers,J.A. Schalken: Cadherin switching in human prostate cancer progression. Cancer Res 2000; 60: 3650-3654.IF 8.2 5
  6. 6. List of Publications G.J.L.H. van Leenders8) G.J.L.H. van Leenders, H.B.P.M. Dijkman, C.A. Hulsbergen-van de Kaa, D.J. Ruiter, J.A. Schalken:Demonstration of intermediate cells during human prostate epithelial differentiation in situ and in vitro usingtriple-staining confocal scanning microscopy. Lab Invest 2000; 80: 1251-1258. IF 4.47) D. Unal, J.P.M. Sedelaar, R.G. Aarnink, G.J.L.H. van Leenders, H. Wijkstra, F.M.J. Debruyne, la Rosette: Three-dimensional contrast-enhanced power Doppler ultrasonography and conventionalexamination methods: the value of diagnostic predictors of prostate cancer. BJU Int 2000; 86: 58-64. IF 3.26) T.E.G. Ruijter, G.J.L.H. van Leenders, G.J. Miller, F.M.J. Debruyne, C.A. Hulsebergen-van de Kaa:Errors in histological grading by prostatic needle biopsy specimens: frequency and predisposing factors. JPathol 2000; 192: 229-233. IF 7.35) G.J.L.H. van Leenders, H.P. Beerlage, T.E.G. Ruijter, J.J.M.C.H. de la Rosette, C.A. van de Kaa:Histopathological changes associated with high intensity focused ultrasound (HIFU) treatment for localisedadenocarcinoma of the prostate. J Clin Pathol 53; 2000: 391-394. IF 2.54) J.P.M. Sedelaar, R.G. Aarnink, G.J.L.H. van Leenders, H.P. Beerlage, F.M.J. Debruyne, H. Wijkstra,J.J.M.C.H. de la Rosette: The application of three-dimensional contrast-enhanced ultrasound to measurevolume of affected tissue after HIFU treatment for localized prostate cancer. Eur Urol 2000; 37: 559-568. IF8.83) H.P. Beerlage, G.J.L.H. van Leenders, G.O.N. Oosterhof, J.A. Witjes, T.E.G. Ruijter, C.A. Hulsbergen-van de Kaa, F.M.J. Debruyne, J.J.M.C.H. de la Rosette: High Intensity Focused Ultrasound (HIFU) followedafter one to two weeks by radical retropubic prostatectomy; results of a prospective study. Prostate 1999; 39:41-46. IF 3.42) M.G. Steffens, O.C. Boerman, W.J.G. Oyen, P.H.M. Kniest, J.A. Witjes, G.O.N. Oosterhof, G.J.L.H. vanLeenders, F.M.J. Debruyne, F.H.M. Corstens, E. Oosterwijk. Intratumoural distribution of two consecutiveinjections of chimeric antibody G250 in primary renal cell carcinoma: implications for fractionated doseradioimmunotherapy. Cancer Res 1999; 59: 1615-1619. IF 8.21) H.G. van der Poel, D. Hessels, G.J.L.H. van Leenders, M.J.G. Bussemakers, J.A. Schalken, J. A. Witjes,F.M.J. Debruyne: Multifocal transitional cell cancer and p53 mutation analysis. J Urol 1998; 160: 124-125. IF3.9Editorial comments4) Eur Urol 2008; 54: 13233) Dutch J Urol 20082) Eur Urol 2007; 52: 1251) Eur Urol 2006; 50:1031 6